Barry Sharples, our Executive Chairman and Co-founder, was one of 10 exclusive global speakers invited to pitch at the invite-only 2024 Longevity Investors Conference in Gstaad, Switzerland. This was a great honor and a recognition of the growing interest in Micregen’s technology.
The event spanned two and a half remarkable days filled with insightful breakout sessions covering various investment and longevity-focused topics.
Barry was asked to present on Micregen’s Secretomix® Platform, an innovative technology offering a multifaceted, disease-modifying approach to regenerative medicine by targeting multiple pathological pathways simultaneously. So far, Micregen’s research has shown significant effects on five of the Hallmarks of Ageing.
Barry shared, “This was a fantastic experience where I connected with many like-minded people, all focused on addressing pressing healthcare challenges related to global ageing. I am already having positive conversations with potential collaborators and investors.”
The Longevity Investors Conference also brought together other leading figures in longevity, including Eric Verdin, CEO/President of the Buck Institute for Research on Ageing; Dr. Nir Barzilai, Director of the Institute for Ageing Research at Albert Einstein College of Medicine; Aubrey de Grey, President and CSO of the LEV Foundation; Bryan Johnson, Founder and CEO of Blueprint, and many more.